Cetoacidosis diabética: Casuística 2008-2012, epidemiología y fisiopatología

• Pablo Olmos ^[1] ; Aníbal Donoso ^[1] ; Juan Pablo Arab ^[1] ; Ian Niklitschek ^[1] ; Nicolás Mertens ^[1] ; Elizabeth Arce ^[1] ; Rosario Lemus ^[1] ; Valentina Serrano ^[1] ; Bruno Grassi ^[1] ; Kristel Strodthoff ^[1] ; Eduardo Abbott ^[1] ; Andrés Aizman ^[1] ; María Verónica González ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 142, Nº. 10, 2014, págs. 1267-1274
• Idioma: español
• Títulos paralelos:
  • Treatment of diabetic ketoacidosis using 2009 American Diabetes Association guidelines
• Enlaces
  • Texto completo
• Resumen

  • Background: During 2009, new guidelines for the treatment of diabetic ketoacidosis were published by the American Diabetes Association. Aim: To assess the impact of new treatment guidelines on the evolution of patients treated for diabetic ketoacidosis (KAD). Patients and Methods: Anonymous data was obtained from computational medical records of patients treated for KAD at our institution two years before (“Traditional Protocol”) and TWO years after (“ADA-2009 Protocol”) the publication of the 2009 American Diabetes Association (ADA) KAD guidelines. Results: Twenty three patients aged 36.5 ± 15.1 years were treated with the traditional method and 23 patients aged 44.4 ± 21.1 years were treated following 2009 ADA guidelines. Among patients treated with the traditional protocol and treated following ADA 2009 guidelines, the diabetes type 1/type 2 ratio was18/5 and 19/16 respectively (p = NS), the glycosylated hemoglobin on admission was 12.6 ± 2.5 and 14.3 ± 2.7% respectively (p = 0.03), minimal blood pH was 7.15 ± 0.14 and 7.19 ± 0.09 respectively (p = NS), bicarbonate was required in seven and no patient respectively (p = 0.01), hypokalemia < 3.5 mEq/L occurred in 78.2 and 48.5% of patients (p = 0.03), the lapse until resolution was 28.7 ± 28.0 and 28.8 ± 20.6 hours (p = NS). Only one patient, treated following ADA 2009 guidelines, died. Conclusions: Introduction of the ADA-2009 protocol for the treatment of KAD resulted in decrease in the use of intravenous bicarbonate and a reduction in the incidence of hypokalemia. There was no impact neither in the lapse until resolution or lethality.